Summary of COVID-19 verapamil studies

1. Navarese et al., Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The ReCOVery-SIRIO randomized trial

144 patient verapamil late treatment RCT: no change in mortality (p=1), 17% higher ventilation (p=1), and 3% worse recovery (p=0.8).
RCT 215 hospitalized non-intensive care COVID-19 patients showing no significant difference in clinical improvement with amiodarone or verapamil. The trial, which aimed to assess the effects of ion channel inhibitors on COVID-19 progression, was prematurely terminated due to slow enrollment.
Sep 2022, Cardiology J., https://journals.viamedica.pl/cardiology_journal/article/view/88627, https://c19p.org/navaresevrp